Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Adafosbuvir, Odalasvir, and Simeprevir in Hepatic Impairment
NCT03277755Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of adafosbuvir and odalasvir in hepatitis C (HCV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of AL-335 and its Metabolites at Day 1, Area Under the Plasma Concentration-time Curve of AL-335 and its Metabolites at Day 1 and 4 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
adafosbuvirodalasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03277755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277755.